ACB Aurora Cannabis Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACB Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
Current Price
Live
$3.55
Analyst Target
$6.41
+80.5%
Upside
52W High
$6.67
52W Low
$3.28
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$201.32M
P/E
N/A
ROE
-15.5%
Profit margin
-22.5%
Debt/Equity
0.18
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
Aurora Cannabis (ACB) exhibits severe financial distress signals, with a Piotroski F-Score of 1/9 indicating extreme weakness in operational and financial health. The absence of an Altman Z-Score and the company's negative profitability metrics—particularly a -22.51% profit margin and -15.51% ROE—underscore deep operational inefficiencies. Despite a low Price/Book (0.51) and Price/Sales (0.54), the stock trades at a significant discount due to persistent losses, negative earnings growth (-94.7% YoY), and a history of massive earnings misses. The lack of dividend, neutral insider activity, and weak technical trend further diminish investor confidence. While the 52-week low is near current levels, the 5-year price decline of 97.5% reflects long-term deterioration.
Key Strengths
Low Price/Book ratio (0.51) suggests potential undervaluation on a balance sheet basis
Strong current ratio (3.06) indicates solid short-term liquidity
Positive operating margin (2.32%) despite negative net income, signaling some operational efficiency
Recent quarter showed a 103.3% Q/Q EPS improvement, indicating possible turnaround momentum
Analyst consensus is 'buy' with a target price of $6.41, implying upside potential
Key Risks
Piotroski F-Score of 1/9 is among the weakest possible, signaling severe financial distress
Negative earnings growth of -94.7% YoY and -93.6% Q/Q reflect deteriorating profitability
No Altman Z-Score available, but the company's negative ROE, high debt-to-equity (0.18), and negative cash flows raise bankruptcy risk
Graham Number and Intrinsic Value are unavailable, indicating no reliable defensive valuation anchor
Historical earnings surprises are extremely volatile and consistently negative, with average surprise of -641.57% over last 4 quarters
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
22
Weak
45
28
20
15
0
AI Verdict
Weak
Key drivers: Extremely low Piotroski F-Score (1/9), Negative earnings and ROE, High volatility in earnings surprises, Lack of reliable valuation metrics, Severe long-term price decline
Confidence
88%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 0.51 suggests deep discount to book value
- Price/Sales of 0.54 is below industry average
Watchpoints
- No Graham Number or intrinsic value estimate available
- Negative earnings and cash flow undermine valuation models
- High volatility in revenue and earnings growth
Future
28/100
Ref Growth rates
Positives
- Recent Q/Q EPS growth of +103.3% may signal improvement
- Analyst target price of $6.41 implies upside potential
Watchpoints
- Revenue growth is only 6.80% YoY, below sector average
- Earnings growth is -94.7% YoY, indicating ongoing losses
- Historical earnings surprises are consistently negative and extreme
Past
20/100
Ref Historical trends
Positives
- Some quarters have beaten estimates (e.g., 2026-02-04, 2025-02-05)
- Operating margin remains positive (2.32%)
Watchpoints
- 25 quarters of earnings data show 18 negative surprises
- Average earnings surprise of -641.57% over last 4 quarters
- 5-year price drop of 97.5% reflects long-term underperformance
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 3.06 is strong
- Quick ratio of 1.05 is acceptable
Watchpoints
- Piotroski F-Score of 1/9 is critically low
- No Altman Z-Score available, but financial health is deteriorating
- Negative ROE (-15.51%) and ROA (-4.36%) indicate poor capital efficiency
- Debt/Equity of 0.18 is low, but not enough to offset losses
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- No history of dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.55
Analyst Target
$6.41
Upside/Downside
+80.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACB and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACB
Aurora Cannabis Inc.
Primary
|
-97.5% | -61.8% | -46.4% | -30.1% | -16.7% | +2.0% |
|
ALEC
Alector, Inc.
Peer
|
-90.7% | -79.9% | +9.5% | -8.8% | +11.4% | +3.7% |
|
ARCT
Arcturus Therapeutics Holdings Inc.
Peer
|
-89.2% | -61.8% | -56.8% | -49.6% | +15.8% | +3.3% |
|
ACH
Accendra Health, Inc.
Peer
|
-92.8% | -89.2% | -85.8% | -73.2% | -22.1% | -16.3% |
|
APYX
Apyx Medical Corporation
Peer
|
-63.3% | +11.5% | +179.1% | +78.0% | +12.1% | -3.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-32.27
PEG Ratio
N/A
P/B Ratio
0.51
P/S Ratio
0.54
EV/Revenue
0.6
EV/EBITDA
-6.88
Market Cap
$201.32M
Profitability
Profit margins and return metrics
Profit Margin
-22.51%
Operating Margin
2.32%
Gross Margin
36.03%
ROE
-15.51%
ROA
-4.36%
Growth
Revenue and earnings growth rates
Revenue Growth
+6.8%
Earnings Growth
-94.7%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-93.6%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.18
Low debt
Current Ratio
3.06
Strong
Quick Ratio
1.05
Good
Cash/Share
$1.91
Quarterly Earnings History
EPS performance vs analyst estimates
2026-06-17
$N/A
2026-02-04
$0.03
+135.3% surprise
2025-11-05
$-0.91
-810.0% surprise
2025-08-06
$-0.27
-1250.0% surprise
Healthcare Sector Comparison
Comparing ACB against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Return on Equity (ROE)
-15.51%
This Stock
vs
-56.84%
Sector Avg
-72.7%
(Below Avg)
Profit Margin
-22.51%
This Stock
vs
-20.8%
Sector Avg
+8.2%
(Better)
Debt to Equity
0.18
This Stock
vs
2.68
Sector Avg
-93.4%
(Less Debt)
Revenue Growth
6.8%
This Stock
vs
61.93%
Sector Avg
-89.0%
(Slower)
Current Ratio
3.06
This Stock
vs
3.47
Sector Avg
-11.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACB
Aurora Cannabis Inc.
|
BEARISH | $201.32M | - | -15.5% | -22.5% | $3.55 | |
|
ALEC
Alector, Inc.
|
BEARISH | $213.94M | - | -122.0% | -156.0% | $1.96 | |
|
ARCT
Arcturus Therapeutics Holdings Inc.
|
BEARISH | $213.96M | - | -27.4% | -68.3% | $7.53 | |
|
ACH
Accendra Health, Inc.
|
BEARISH | $163.2M | - | -196.4% | -12.4% | $2.11 | |
|
APYX
Apyx Medical Corporation
|
BEARISH | $159.19M | - | -168.1% | -30.4% | $3.88 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-09-23 | Martin (Miguel) | Senior Officer of Issuer | Stock Award | 60,024 | - |
| 2025-09-23 | Schick (Lori) | Senior Officer of Issuer | Stock Award | 13,265 | - |
| 2025-09-23 | Schick (Lori) | Senior Officer of Issuer | Disposition in the public market at price 5.12 per | 7,352 | $37,627 |
| 2025-09-19 | Martin (Miguel) | Senior Officer of Issuer | Stock Award | 860 | - |
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning ACB from our newsroom.
Newest → oldest
No matching news yet.